Currently Enrolling Clinical Trials for IBC
(designed for IBC patients or building on IBC research)

Neoadjuvant trials:

A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer
Sites/sponsors: MD Anderson, investigator-initiated trial
Principal investigator(s): Naoto Ueno, MD PhD at MD Anderson
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT02876107](https://clinicaltrials.gov/ct2/show/NCT02876107)

A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer (completed already), and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
Sites/sponsors: MD Anderson, investigator-initiated trial
Principal investigator(s): Bora Lim, MD at MD Anderson
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT03101748](https://clinicaltrials.gov/ct2/show/NCT03101748)

TBCRC 039: Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Sites/sponsors: Multi-center (8 sites) Translational Breast Cancer Research Consortium sponsored trial
Principal investigator(s): National PI is Beth Overmoyer, MD at Dana Farber
Link for information: [https://clinicaltrials.gov/ct2/show/NCT02876302](https://clinicaltrials.gov/ct2/show/NCT02876302)

A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Sites/sponsors: Dana Farber, investigator-initiated trial
Principal investigator(s): Beth Overmoyer, MD at Dana Farber
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT02623972](https://clinicaltrials.gov/ct2/show/NCT02623972)

Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Sites/sponsors: City of Hope, investigator-initiated trial
Principal investigator(s): Yuan Yuan, MD PhD at City of Hope
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT01525966](https://clinicaltrials.gov/ct2/show/NCT01525966)
Adjuvant trials:

**Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer**
Sites/sponsors: Multi-center, NCI/SWOG cooperative group sponsored trial
Principal investigator(s): National PI is Reshma Jagsi, MD at the University of Michigan
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT03598257](https://clinicaltrials.gov/ct2/show/NCT03598257)

**A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy**
Sites/sponsors: MD Anderson, investigator-initiated trial
Principal investigator(s): Bora Lim, MD at MD Anderson
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT02971748](https://clinicaltrials.gov/ct2/show/NCT02971748)

Metastatic trials:

**A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy**
Sites/sponsors: MD Anderson, investigator-initiated trial
Principal investigator(s): Naoto Ueno, MD PhD at MD Anderson
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT02411656](https://clinicaltrials.gov/ct2/show/NCT02411656)

**A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer**
Sites/sponsors: MD Anderson, Genentech supported, investigator-initiated trial
Principal investigator(s): Bora Lim, MD at MD Anderson
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT03202316](https://clinicaltrials.gov/ct2/show/NCT03202316)

**A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial**
Sites/sponsors: Northwestern University, investigator-initiated
Principal investigator(s): Ricardo Costa, MD at Northwestern University
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT02892734](https://clinicaltrials.gov/ct2/show/NCT02892734)

**A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)**
Sites/sponsors: Multi-center, company-sponsored trial (BergenBio)
Principal investigator(s): Multiple
Link for more information: [https://clinicaltrials.gov/ct2/show/NCT03184558](https://clinicaltrials.gov/ct2/show/NCT03184558)